Navamedic ASA provided revenue guidance for the first half of 2022. The company has decided to provide a trading update based on estimated organic revenue growth for the first half of 2022 in excess of 30%. The high revenue growth is a result of a strong June 2022 and is driven by significant demand for Mysimba as well as other key products in the portfolio.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.9 NOK | +0.58% | +2.65% | -4.90% |
05-06 | Navamedic Rolls Out Erectile Dysfunction Drug in Sweden | MT |
04-30 | Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.90% | 57.56M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- NAVA Stock
- News Navamedic ASA
- Navamedic ASA Provides Revenue Guidance for the First Half of 2022